{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:52:35Z","timestamp":1789602755974,"version":"build-2803163510"},"reference-count":30,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"inova diagnostics"},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["724517"],"award-info":[{"award-number":["724517"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In rheumatoid arthritis (RA) around two-thirds of patients are autoantibody positive for rheumatoid factor, anti-citrullinated protein antibodies and\/or anti-carbamylated protein antibodies. The remaining seronegative subgroup of patients is clinically heterogeneous and thus far, biomarkers predicting the disease course are lacking. Therefore, we analysed the value of other autoantibodies in RA directed against malondialdehyde-acetaldehyde adducts (MAA) and advanced glycation end-products (AGE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In sera of 648 patients with RA and 538 patients without RA from the Leiden Early Arthritis Clinic, anti-MAA and anti-AGE IgG antibody levels were measured using ELISA. Associations between genetic risk factors, acute phase reactants, radiological joint damage, remission and anti-PTM positivity were investigated using regression, correlation and survival analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Anti-AGE and anti-MAA were most prevalent in RA (44.6% and 46.1% respectively) but were also present in non-RA arthritis patients (32.9% and 30.3% respectively). Anti-AGE and anti-MAA antibodies were associated with HLA-DRB1*03 within seronegative RA (OR=1.98, p=0.003, and OR=2.37, p&lt;0.001, respectively) and, for anti-AGE also in non-RA arthritis patients (OR=2.34, p&lt;0.001). Presence of anti-MAA antibodies was associated significantly with markers of inflammation, erythrocyte sedimentation rate and C reactive protein, in all groups independent of anti-AGE. Interestingly, the presence of anti-AGE and anti-MAA antibodies was associated with radiological progression in patients with seronegative RA, but not evidently with sustained drug-free remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-AGE and anti-MAA were present in around 45% of RA patients and 30% of non-RA arthritis patients, and although not specific for RA, their presence associated with HLA, inflammation and, for RA, with clinical outcomes especially in patients with seronegative RA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003480","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:22:11Z","timestamp":1701433331000},"page":"e003480","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-1887","authenticated-orcid":false,"given":"Michelle D","family":"van den Beukel","sequence":"first","affiliation":[{"name":"Immunology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-0530","authenticated-orcid":false,"given":"Tineke J","family":"van Wesemael","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-9052","authenticated-orcid":false,"given":"Anna Titia W","family":"Hoogslag","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole V","family":"Borggreven","sequence":"additional","affiliation":[{"name":"Immunology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-7520","authenticated-orcid":false,"given":"Tom WJ","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette HM","family":"van der Helm-van Mil","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-6414","authenticated-orcid":false,"given":"Ren\u00e9 EM","family":"Toes","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-5879","authenticated-orcid":false,"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-2290","authenticated-orcid":false,"given":"Leendert A","family":"Trouw","sequence":"additional","affiliation":[{"name":"Immunology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2025090312493534000_9.4.e003480.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.05.007"},{"key":"2025090312493534000_9.4.e003480.2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1316"},{"key":"2025090312493534000_9.4.e003480.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114465108"},{"key":"2025090312493534000_9.4.e003480.4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.gpb.2018.06.004","article-title":"PTMD: a database of human disease-associated post-translational modifications","volume":"16","author":"Xu","year":"2018","journal-title":"Genom Proteom Bioinform"},{"key":"2025090312493534000_9.4.e003480.5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200114002"},{"key":"2025090312493534000_9.4.e003480.6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3897\/folmed.62.e47788","article-title":"Serum levels of antibodies to advanced glycation end products in patients with type 2 diabetes mellitus and hypertension","volume":"62","author":"Nikolov","year":"2020","journal-title":"Folia Med (Plovdiv)"},{"key":"2025090312493534000_9.4.e003480.7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.38969","article-title":"Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis","volume":"67","author":"Thiele","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090312493534000_9.4.e003480.8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF03346408","article-title":"Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation","volume":"31","author":"Buongiorno","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2025090312493534000_9.4.e003480.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1998.tb03973.x"},{"key":"2025090312493534000_9.4.e003480.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.21302"},{"key":"2025090312493534000_9.4.e003480.11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/art.40738","article-title":"Specific association of HLA-Drb1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis","volume":"71","author":"Regueiro","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312493534000_9.4.e003480.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205109"},{"key":"2025090312493534000_9.4.e003480.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.41"},{"key":"2025090312493534000_9.4.e003480.14","article-title":"Shared HLA class II in six autoimmune diseases in Latin America: a meta-analysis","volume":"2012","author":"Cruz-Tapias","year":"2012","journal-title":"Autoimmune Dis"},{"key":"2025090312493534000_9.4.e003480.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq230"},{"key":"2025090312493534000_9.4.e003480.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090312493534000_9.4.e003480.17","first-page":"S100","article-title":"The leiden early arthritis clinic","volume":"21","author":"van Aken","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312493534000_9.4.e003480.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21385"},{"key":"2025090312493534000_9.4.e003480.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200724"},{"key":"2025090312493534000_9.4.e003480.20","first-page":"261","article-title":"How to read radiographs according to the sharp\/Van der heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025090312493534000_9.4.e003480.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02671-z","article-title":"Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution","volume":"24","author":"Verstappen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090312493534000_9.4.e003480.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002079","article-title":"Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations","volume":"8","author":"Monahan","year":"2022","journal-title":"RMD Open"},{"key":"2025090312493534000_9.4.e003480.23","doi-asserted-by":"publisher","DOI":"10.1007\/s005920070025"},{"key":"2025090312493534000_9.4.e003480.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.488"},{"key":"2025090312493534000_9.4.e003480.25","doi-asserted-by":"crossref","DOI":"10.1186\/ar3538","article-title":"Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease","volume":"13","author":"de Groot","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025090312493534000_9.4.e003480.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.12.1307"},{"key":"2025090312493534000_9.4.e003480.27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.55563\/clinexprheumatol\/0ms5pk","article-title":"Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls","volume":"39","author":"Verheul","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312493534000_9.4.e003480.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213724"},{"key":"2025090312493534000_9.4.e003480.29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.intimp.2018.01.022","article-title":"Malondialdehyde-acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions","volume":"56","author":"Mikuls","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"2025090312493534000_9.4.e003480.30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/sji.12265","article-title":"Anti-citrullinated peptide antibodies in sudanese patients with leishmania donovani infection exhibit reactivity not dependent on citrullination","volume":"81","author":"\u00c5hlin","year":"2015","journal-title":"Scand J Immunol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:49:43Z","timestamp":1756928983000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/rmdopen-2023-003480"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003480","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}